Causaly Unveils New Agentic AI for Enhanced Biomedical Research Discovery

Causaly Introduces Agentic AI for Scientific Discovery

In a significant development for the life sciences industry, Causaly has unveiled a new suite of scientific AI agents aimed at enhancing research capabilities for biomedical teams. This advanced technology, introduced on March 31, 2025, is expected to revolutionize how scientists approach drug discovery by granting access to the most extensive biomedical knowledge available in the industry.

Causaly Discover, powered by these AI agents, allows research teams to effortlessly access, analyze, and synthesize vast amounts of information from the Causaly Knowledge Graph, along with other internal and external data sources. This integration enables researchers to address complex biomedical inquiries with unprecedented speed and precision, thereby greatly improving research outcomes.

The platform, developed over a dedicated seven-year period, utilizes sophisticated search algorithms that link an impressive 500 million facts and 70 million directional relationships across eight relationship types within a knowledge graph. Researchers utilizing Causaly have reported savings of up to 90% in the time needed to identify and validate viable targets for safe and effective therapy development. Notably, prominent biopharmaceutical companies such as Novo Nordisk are already leveraging this groundbreaking technology to expand their research efforts and enhance the efficiency, quality, and speed of target pipelines.

"We are fundamentally redefining the drug discovery process by facilitating how research teams amalgamate knowledge across the entire biomedical landscape rather than being confined to conventional literature searches," stated Yiannis Kiachopoulos, Causaly’s co-founder and CEO. "Causaly Discover acts as the essential hub for all information vital to expediting therapies to market. The introduction of new AI agents allows scientists to derive deeper insights, enabling them to transition swiftly from questions to confident decisions, all with unparalleled speed and transparency."

As the cost of developing a new drug can soar beyond $2 billion and the entire process may stretch over a decade, pinpointing the correct research target is crucial. Causaly’s AI agents are crafted specifically for life sciences, significantly reducing the time and effort spent piecing together disparate data sources while sifting through immense volumes of biomedical information. This optimization not only helps in discovering new biomarkers but also in prioritizing targets and understanding disease biology more efficiently.

One of the standout capabilities of Causaly Discover is its ability to answer complex biomedical questions in minutes instead of weeks. Additionally, it automatically generates detailed reports, streamlining time spent on reviewing insights. The seamless integration of Causaly with external resources, including the Human Protein Atlas, as well as live web search results, enhances the user experience significantly. The AI platform ensures that every insight derived from Causaly Discover is traceable and supported by credible resources, simplifying the verification of results and enabling researchers to pose follow-up questions using Causaly Copilot.

Moreover, research teams can collaborate more effectively by centralizing, saving, sharing, and commenting on scientific findings within a consolidated workspace. This workspace comes equipped with automated alerts that summarize findings and notify researchers of the latest evidence. Presently, the AI agents in Causaly Discover are available for early access with plans for general availability to all customers by May 2025.

For those looking to delve deeper into how Causaly Discover, supported by new AI agents, allows scientists to refine, verify, and share research with greater accuracy and transparency, more information can be found on Causaly’s blog. Known as a leader in AI tailored for the life sciences sector, Causaly empowers biopharmaceutical firms to uncover, visualize, and interpret biomedical information while automating essential research workflows. To discover how Causaly is propelling drug discovery through innovative AI technologies and ensuring critical treatments reach patients more swiftly, please visit www.causaly.com.

In summary, Causaly's introduction of Agentic AI marks a pivotal moment in scientific research, streamlining processes and ensuring that scientists can operate with greater effectiveness and insight than ever before.